Latest Kaiser Health News Stories
Doctors are advising patients to be sure to fill medication orders now or are giving away drugs to make sure children have enough if their insurance disappears.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Harvesting U.S. crops has been left to an aging population of farmworkers whose health has suffered from decades of hard labor. Older workers have a greater chance of getting injured and of developing chronic illnesses.
The painful condition caused by the chickenpox virus will strike 1 in 3 Americans during their lifetimes — most between ages 60 and 70, but those in their 50s have reason to arm themselves.
Overtreatment of breast cancer and other diseases is pervasive, burdening patients and the health care system with enormous costs and needless suffering.
After weathering the catastrophe in New Orleans 12 years ago, Dr. Ruth Berggren moved to Texas, where she again finds herself in the center of a hurricane crisis. In a Q&A, she draws parallels between the harrowing events and pinpoints risks in Harvey’s aftermath.
Death rates for older adults with asthma run five times higher than younger people, and serious complications are far more common.
A long history of racism and cruel experimentation in health care are among the reasons African-American families oppose donating patients’ brains for study.
The new law will help people with chronic conditions that require multiple prescriptions cut down on their shuttles to the drug store and could improve adherence to their drugs.
The market for wound care products booms among a growing older and diabetic patient pool, but many treatments are untested and funding for research falls short.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
One in 5 heart attack patients suffers from severe depression, yet many get little or no treatment that could ease their suffering or save their lives.
Some health plans are beginning to offer free maintenance care for people with chronic health problems, hoping that spending a little more early on will save a lot of money in the long run.
A study published by the Journal of the American Heart Association showed that sudden cardiac arrests dropped by 17 percent in one Oregon county after people gained health insurance through the Affordable Care Act.
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Once-fatal childhood diseases, like cystic fibrosis, congenital heart disease and sickle cell anemia, now can be survived into adulthood. But when those patients become too old to see pediatricians, it can be difficult for them to find physicians familiar with their conditions.
One in 9 Medicare enrollees have COPD and many of them can’t afford the inhalers that keep them out of the emergency room.